Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07309289

PHASE3

NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

Sponsor: Shanghai Zhongshan Hospital

View on ClinicalTrials.gov

Summary

To explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.

Official title: NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer: a Multicentre, Open-label, Randomised Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

144

Start Date

2025-07-01

Completion Date

2029-09-01

Last Updated

2025-12-30

Healthy Volunteers

Conditions

Metastatic Colorectal Cancer (CRC)

Interventions

DRUG

NALIRIFOX plus targeted therapy

Drug: Irinotecan Liposome Irinotecan liposome injection will be administered by an intravenous infusion at the dose of 50 mg/m\^2, d1, 14 days per cycle. Drug: Oxaliplatin 75 mg/m\^2, intravenously infusion, d1, 14 days per cycle. Drug: 5-FU 2400mg/m\^2, intravenous infusion, d1-2, 14 days per cycle. Drug: LV/l-LV 400mg/m\^2 or 200mg/m\^2 , intravenous infusion, d1, 14 days per cycle. Drug: Bevacizumab 5mg/kg, intravenous infusion, d1, 14 days per cycle. Drug: Cetuximab 500mg/m\^2, intravenous infusion, d1, 14 days per cycle.

DRUG

FOLFOX plus targeted therapy

Drug: Oxaliplatin 85 mg/m\^2, intravenously infusion, d1, 14 days per cycle. Drug: 5-FU 2400mg/m\^2, intravenous infusion, d1-2, 14 days per cycle. Drug: LV/l-LV 400mg/m\^2 or 200mg/m\^2 , intravenous infusion, d1, 14 days per cycle. Drug: Bevacizumab 5mg/kg, intravenous infusion, d1, 14 days per cycle. Drug: Cetuximab 500mg/m\^2, intravenous infusion, d1, 14 days per cycle.

Inclusion Criteria: * ≥18 years old * Histopathologically confirmed patient with an inoperable metastatic colorectal adenocarcinoma * The unresectable stage of metastatic disease has not received any systemic antitumor therapy * For subjects previously receiving neoadjuvant or adjuvant therapy, the date of first discovery of disease progression must be at least 12 months removed from the date of last administration of neoadjuvant or adjuvant therapy * The presence of at least 1 measurable lesion that can be evaluated according to the RECIST v1.1 criteria * ECOG 0\~1 * Normal bone marrow and organ function * Understand the situation of this study, patients and/or legal representatives voluntarily agree to participate in this study and sign informed consent form Exclusion Criteria: * Patients with known MSI-H or dMMR who were evaluated by investigators as suitable for treatment with immune checkpoint inhibitors. * Patients allergic to the investigational drug and its excipients * Underweight (body mass index \[BMI\]\<18.5 kg/m\^2 * Known or suspected central nervous system metastasis * Received irinotecan before enrollment * Had undergone surgery and other oncologic treatments within the first 4 weeks of enrollment * Previous treatment-related toxicity didn't return to NCI-CTCAE v5.0 class I or below. * The use of CYP3A, CYP2C8, and UGT1A1 inhibitors or inducers couldn't be discontinued or were not discontinued within 2 weeks prior to enrollment * Serious gastrointestinal disorders * Interstitial lung disease * Tendency of arterial embolism and massive bleeding within 6 months before enrollment (except surgical bleeding) * Patients with fluid accumulation that couldn't reach a stable state and small amount of pleural effusion or ascites on imaging without clinical symptoms could be enrolled * Intestinal obstruction, or a risk of intestinal obstruction in the short term * Gastrointestinal perforation, intraperitoneal abscess, and fistula * Any serious or uncontrolled systemic disease, including uncontrolled high blood pressure, heart disease, active bleeding, active viral infection, etc * Have had other malignancies within the past 5 years or currently, except cured cervical carcinoma in situ, uterine carcinoma in situ, and non-melanoma skin cancer * Patients of childbearing age who refuse to take contraceptives, women who are pregnant or breastfeeding * The researchers didn't consider it appropriate to participate in this study

Locations (1)

Shanghai Zhongshan Hospital

Shanghai, China